AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17565921 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 0
Study 17565921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15500894 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose brachytherapy (12 Gy)
Number of subjects: 209
Study 15500894 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding metal stent placement
Number of subjects: 209
Study 11549798 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/CMA (Belara)
Number of subjects: 199
Study 11549798 — intervention group
Group type: COMPARATOR
Intervention: EE/LNG (Microgynon)
Number of subjects: 199
Study 10456135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg daily (increased to 6 mg if no satisfactory response)
Number of subjects: 41
Study 10456135 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg daily (increased to 50 mg if necessary)
Number of subjects: 41
Study 7524263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous, polyethyleneglycol‐treated, human immunoglobulin at 200 mg/kg per day for five consecutive days (group A)
Number of subjects: 451
Study 7524263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous, polyethyleneglycol‐treated, human immunoglobulin at 400 mg/kg per day for five consecutive days (group B)
Number of subjects: 451
Study 7524263 — intervention group
Group type: COMPARATOR
Intervention: Freeze‐dried, sulfonated human immunoglobulin at 200 mg/kg per day for five consecutive days (group C)
Number of subjects: 451
Study 3601609 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading only
Number of subjects: 300
Study 3601609 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening only
Number of subjects: 300
Study 3601609 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading and listening
Number of subjects: 300
Study 3601609 — intervention group
Group type: COMPARATOR
Intervention: Control group (below average readers)
Number of subjects: 300
Study 29265922 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine visits
Number of subjects: 222
Study 29265922 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face care
Number of subjects: 222
Study 27259583 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (TCS) application via soak and smear (SS)
Number of subjects: 45
Study 27259583 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid (TCS) application to dry skin
Number of subjects: 45
Study 23927381 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented drink containing soy isoflavones, lycopene, vitamin C, and vitamin E
Number of subjects: 0
Study 23927381 — intervention group
Group type: COMPARATOR
Intervention: Capsule containing fish oil (Control)
Number of subjects: 0
Study 24438569 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete denture with lingualized occlusion
Number of subjects: 70
Study 24438569 — intervention group
Group type: COMPARATOR
Intervention: Complete denture with anatomic occlusion
Number of subjects: 70
Study 20837284 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care reminders (EUCR)
Number of subjects: 3547
Study 20837284 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers plus positive consequences of getting mammograms (BarriConCall+)
Number of subjects: 3547
Study 20837284 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers plus negative consequences of not getting mammograms (BarriConCall‐)
Number of subjects: 3547
Study 20837284 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers only (BarriCall)
Number of subjects: 3547
Study 17658632 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins and fibrates (specific types not mentioned)
Number of subjects: 0
Study 17658632 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study 17658632 — intervention group
Group type: COMPARATOR
Intervention: Fibrates (specific types not mentioned)
Number of subjects: 0
Study 17658632 — intervention group
Group type: COMPARATOR
Intervention: Statins combined with gemfibrozil
Number of subjects: 0
Study 17658632 — intervention group
Group type: COMPARATOR
Intervention: Statins combined with fenofibrate, bezafibrate, or ciprofibrate
Number of subjects: 0
Study 16386999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU/day of vitamin E
Number of subjects: 0
Study 16386999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11842026 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O(2) (hyperoxia)
Number of subjects: 6
Study 11842026 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO(2) and 15% O(2) (hypoxic hypercapnia)
Number of subjects: 6
Study 11842026 — intervention group
Group type: COMPARATOR
Intervention: Normal air
Number of subjects: 6
Study 10564677 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American patients
Number of subjects: 663
Study 10564677 — intervention group
Group type: COMPARATOR
Intervention: Caucasian patients
Number of subjects: 663
Study 7747682 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol (200 mg/day)
Number of subjects: 6400
Study 7747682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6400
Study 2117891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of recombinant interferon-beta (IFN-beta) at 6 x 10(6) units continuously for 14 days from the day of operation.
Number of subjects: 33
Study 2117891 — intervention group
Group type: COMPARATOR
Intervention: Control group received MMC, 20 mg (i.v.) on the day of operation and 5-FU, 200 mg (p.o.) for 1 year from 2 weeks after operation.
Number of subjects: 33
Study 2117891 — intervention group
Group type: COMPARATOR
Intervention: Both groups were compared for 3-year survival rate and disease-free survival rate.
Number of subjects: 33
Study 6895415 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy + MOPP
Number of subjects: 3
Study 6895415 — intervention group
Group type: COMPARATOR
Intervention: Involved-field radiotherapy
Number of subjects: 3
Study 6895415 — intervention group
Group type: COMPARATOR
Intervention: Extended-field radiotherapy
Number of subjects: 3
Study 6895415 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone for limited mediastinal disease
Number of subjects: 3
Study 6895415 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone for extensive mediastinal and hilar disease
Number of subjects: 3
Study 6895415 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP alone
Number of subjects: 3
Study 30660733 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin exposure (new initiators)
Number of subjects: 73944
Study 30660733 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin exposure (existing users)
Number of subjects: 73944
Study 30660733 — intervention group
Group type: COMPARATOR
Intervention: Baseline total cholesterol increase (statin-naïve subjects)
Number of subjects: 73944
Study 30660733 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin exposure (cumulative years)
Number of subjects: 73944
Study 28567578 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, two boluses at 3 and 6 hours later (group A)
Number of subjects: 159
Study 28567578 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, one bolus at 9 hours later (group B)
Number of subjects: 159
Study 28567578 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, two boluses at 9 and 12 hours later (group C)
Number of subjects: 159
Study 28567578 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 159
Study 26458939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin 1000 mg
Number of subjects: 18
Study 26458939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin 500 mg
Number of subjects: 18
Study 26458939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23433688 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day of DHA
Number of subjects: 0
Study 23433688 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil capsules
Number of subjects: 0
Study 21243486 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nasal nicotine
Number of subjects: 41
Study 21243486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20031736 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus eptifibatide
Number of subjects: 400
Study 20031736 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 400
Study 17044132 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 2729
Study 17044132 — intervention group
Group type: COMPARATOR
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 2729
Study 15117090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg
Number of subjects: 355
Study 15117090 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 50 mg
Number of subjects: 355
Study 15117090 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 355
Study 15117090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 11673582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vigabatrin (18-36 mg/kg/day)
Number of subjects: 142
Study 11673582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vigabatrin (100-148 mg/kg/day)
Number of subjects: 142
Study 11673582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vigabatrin
Number of subjects: 142
Study 11673582 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tuberous sclerosis
Number of subjects: 142
Study 11673582 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (both doses)
Number of subjects: 142
Study 9502190 — intervention group
Group type: EXPERIMENTAL
Intervention: euglycaemic clamp [glucose 5 mmol L(‐1)]
Number of subjects: 9
Study 9502190 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperglycaemic clamp [glucose 15 mmol L(‐1)]
Number of subjects: 9
Study 9502190 — intervention group
Group type: EXPERIMENTAL
Intervention: euglycaemic hyperinsulinaemic clamp [glucose 5 mmol L(‐l)]
Number of subjects: 9
Study 9502190 — intervention group
Group type: EXPERIMENTAL
Intervention: intrajejunal infusion of lipid (Lipofundin medium‐chained triglyceride 10%)
Number of subjects: 9
Study 9502190 — intervention group
Group type: COMPARATOR
Intervention: exogenous or endogenous hyperinsulinaemia
Number of subjects: 9
Study 7857119 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (RP 56976)
Number of subjects: 12
Study 2122343 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg daily
Number of subjects: 15
Study 2122343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 354372 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperazine (ascaricide)
Number of subjects: 37
Study 354372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30124725 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ)
Number of subjects: 212
Study 30124725 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 212
Study 30124725 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene (TAZ)
Number of subjects: 212
Study 30124725 — intervention group
Group type: COMPARATOR
Intervention: Halobetasol (HP)
Number of subjects: 212
Study 26205759 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus with oral prednisolone (TAC*)
Number of subjects: 70
Study 26205759 — intervention group
Group type: COMPARATOR
Intervention: Modified Ponticelli regimen (MPR)
Number of subjects: 70
Study 26205759 — intervention group
Group type: COMPARATOR
Intervention: Cyclical CTX/steroids (MPR)
Number of subjects: 70
Study 24604685 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) combined with methylprednisolone (MPred) - EPO dosage: 20,000 U/24 h, MPred dosage: 1,000 mg/24 h for five consecutive days.
Number of subjects: 20
Study 24604685 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MPred) alone - MPred dosage: 1,000 mg/24 h for five consecutive days, placebo for EPO.
Number of subjects: 20
Study 23048057 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffold
Number of subjects: 45
Study 20410083 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (10 mg iron, 375 microg vitamin A, 4.2 mg zinc, 225 microg folic acid, 1.35 microg vitamin B-12 per child per day)
Number of subjects: 499
Study 20410083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study 20410083 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Number of subjects: 499
Study 18417532 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella enterica serovar Typhi Ty21a expressing H pylori urease or HP0231
Number of subjects: 58
Study 18417532 — intervention group
Group type: COMPARATOR
Intervention: Ty21a (control)
Number of subjects: 58
Study 18417532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both vaccinees and controls)
Number of subjects: 58
Study 18417532 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell response
Number of subjects: 58
Study 16040923 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol [300 mg of iodine per milliliter]
Number of subjects: 125
Study 16040923 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol [320 mg I/mL]
Number of subjects: 125
Study 16040923 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol [350 mg I/mL]
Number of subjects: 125
Study 16040923 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol [350 mg I/mL]
Number of subjects: 125
Study 16040923 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol [400 mg I/mL]
Number of subjects: 125
Study 12930007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 343
Study 12930007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.25 mg
Number of subjects: 343
Study 12930007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 343
Study 12930007 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 343
Study 10230955 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (0.2 mg/kg) during cooling and rewarming periods of CPB
Number of subjects: 43
Study 8681614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal-CPAP (N-CPAP)
Number of subjects: 76
Study 8681614 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (uvulopalatopharyngoplasty [UPPP] with or without mandibular osteotomy)
Number of subjects: 76
Study 8681614 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 76
Study 1792820 — intervention group
Group type: COMPARATOR
Intervention: Daflon 500 mg
Number of subjects: 20
Study 6824358 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent and midstrength topical steroids
Number of subjects: 26
Study 6824358 — intervention group
Group type: COMPARATOR
Intervention: Simple lubricating agents
Number of subjects: 26
Study 6824358 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 26
Study 6824358 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated five times weekly
Number of subjects: 26
Study 6824358 — intervention group
Group type: COMPARATOR
Intervention: Irradiated three times weekly
Number of subjects: 26
Study 3902420 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (2.7 g per day for 18 weeks)
Number of subjects: 62
Study 3902420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearing capsules)
Number of subjects: 62
Study 31545734 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive mode
Number of subjects: 24
Study 31545734 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbing mode
Number of subjects: 24
Study 31545734 — intervention group
Group type: COMPARATOR
Intervention: Transparent mode
Number of subjects: 24
Study 30120406 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified biscuit (BG)
Number of subjects: 108
Study 30120406 — intervention group
Group type: COMPARATOR
Intervention: Capsule vitamin D (CG)
Number of subjects: 108
Study 30120406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampoule vitamin D (AG)
Number of subjects: 108
Study 26826729 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 52
Study 26826729 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent drinkers
Number of subjects: 52
Study 26826729 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol impairment
Number of subjects: 52
Study 24906450 — intervention group
Group type: EXPERIMENTAL
Intervention: Community (church)‐based lifestyle intervention programme
Number of subjects: 300
Study 24906450 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 300
Study 22878647 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg/day) and E (400 I.U./day) supplementation for 1 year
Number of subjects: 23
Study 22878647 — intervention group
Group type: COMPARATOR
Intervention: Control group (cholinergic medication only)
Number of subjects: 23
Study 20197767 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group (received the letter of invitation)
Number of subjects: 115
Study 20197767 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive the letter of invitation)
Number of subjects: 115
Study 18716766 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRA with 3D axial inflow technique
Number of subjects: 37
Study 18716766 — intervention group
Group type: COMPARATOR
Intervention: 1.5T MRA
Number of subjects: 37
Study 18716766 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced MRA (CE-MRA) at 3T
Number of subjects: 37
Study 18716766 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRA
Number of subjects: 37
Study 15832045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation for 8 weeks from hospital discharge
Number of subjects: 136
Study 15832045 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 136
Study 14634941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5%
Number of subjects: 50
Study 14634941 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 50
Study 10747768 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 100
Study 10747768 — intervention group
Group type: COMPARATOR
Intervention: Self-administered diaries
Number of subjects: 100
Study 9033826 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: Propofol and fentanyl then isoflurane 1%
Number of subjects: 36
Study 9033826 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: TIVA with propofol and fentanyl
Number of subjects: 36
Study 9033826 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Propofol then an epidural lumbar block with bupivacaine 0.25% (single shot) and continuous propofol i.v. infusion
Number of subjects: 36
Study 1889248 — intervention group
Group type: EXPERIMENTAL
Intervention: D53 (Ribomunyl)
Number of subjects: 12
Study 1889248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6394515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day for 7 days)
Number of subjects: 40
Study 6394515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil (500 mg twice a day for 7 days)
Number of subjects: 40
Study 30784788 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release group (n=18) receiving four sessions of myofascial treatment, each lasting 40 minutes.
Number of subjects: 36
Study 30784788 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18) receiving sham myofascial release.
Number of subjects: 36
Study 28446232 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) interventions implemented at facility and health district levels for 18 months.
Number of subjects: 0
Study 28446232 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) teams established at the district and MCH clinic levels.
Number of subjects: 0
Study 26775208 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP-2 or BMP-7 with autologous bone grafting (24 patients total; 4 with BMP-2, 20 with BMP-7)
Number of subjects: 49
Study 26775208 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone grafting without BMP (25 patients)
Number of subjects: 49
Study 24363039 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strength training
Number of subjects: 17
Study 24363039 — intervention group
Group type: COMPARATOR
Intervention: Arm ergometry
Number of subjects: 17
Study 21994966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (average daily dose of 12.0 ± 2.7 mg/m² for PAI; 15.5 ± 7.8 mg/m² for CAH)
Number of subjects: 122
Study 21994966 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 122
Study 21994966 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment in PAI women
Number of subjects: 122
Study 21994966 — intervention group
Group type: COMPARATOR
Intervention: Non-DHEA treatment in PAI women
Number of subjects: 122
Study 19118799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise regimes (three different types)
Number of subjects: 0
Study 19118799 — intervention group
Group type: EXPERIMENTAL
Intervention: Stork test (one-legged standing test)
Number of subjects: 0
Study 17718368 — intervention group
Group type: EXPERIMENTAL
Intervention: Short glide with a 40 ms or less silent gap
Number of subjects: 0
Study 17718368 — intervention group
Group type: EXPERIMENTAL
Intervention: Long glide with a 40 ms or less silent gap
Number of subjects: 0
Study 17718368 — intervention group
Group type: EXPERIMENTAL
Intervention: No substitute energy in the gap
Number of subjects: 0
Study 15098491 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health education and health promotion
Number of subjects: 300000
Study 15098491 — intervention group
Group type: COMPARATOR
Intervention: Control community
Number of subjects: 300000